** Vaccine maker Moderna MRNA.O on Friday trimmed its 2025 revenue forecast after UK deliveries of some COVID vaccines were deferred to next year.

** The revised forecast of between $1.5 billion and $2.2 billion reflects ongoing headwinds for the vaccine maker, which is grappling with slumping demand for COVID-19 shots, a slower-than-expected RSV rollout and regulatory delays in its new product pipeline.

OPTIMISTIC ON CO'S CANCER VACCINE PIPELINE

** Morningstar ( fair value estimate: $85) says its most enthusiastic about the company's oncology pipeline

** "We think investors are focused on policy issues and near-term uncertainty around the CMV readout, rather than what we see as the more valuable oncology pipeline led by intismeran"

** TD Cowen ("hold" PT: $25) says eight potential regulatory filings and approvals, including for MRNA's experimental respiratory vaccines and cancer vaccine intismeran, could support Moderna's goal of a 2028 break even

** "Collectively, these programs represent a $30 bln total addressable market"

** Berenberg ("hold," PT: $30) says late-stage data for MRNA's Merck & Co-partnered individualized cancer vaccine, intismeran, is the most important pipeline catalyst

** Piper Sandler ("overweight", PT: $69) says, "We forecast new vaccine approvals will grow product sales from $1.7 billion this year to $2.9 billion in 2026 and $4.3 billion in 2027"

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))